These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29741285)

  • 41. Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta-analysis.
    Zhou R; Yang L; Zhang B; Gu Y; Kong T; Zhang W; Sun L; Liu C; Kong N; Li J; Shi J
    J Viral Hepat; 2023 Oct; 30(10):793-802. PubMed ID: 37533208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Manifestations of perihepatic lymph nodes in acute flare of chronic hepatitis B: association with HBeAg status and with HBeAg seroconversion.
    Ko YL; Sun CS; Chung KM; Lin YM; Feng IC; Sheu MJ; Koay LB; Lin CY; Ho CH; Kuo HT
    PLoS One; 2015; 10(2):e0117590. PubMed ID: 25689069
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Type 2 diabetes and hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B.
    Li Q; Li WW; Yang X; Fan WB; Yu JH; Xie SS; Liu L; Ma LX; Chen SJ; Kato N
    Int J Cancer; 2012 Sep; 131(5):1197-202. PubMed ID: 22052244
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatocellular carcinoma incidence in noncirrhotic patients with chronic hepatitis B and patients with cirrhosis of all etiologies.
    Do AL; Wong CR; Nguyen LH; Nguyen VG; Trinh H; Nguyen MH
    J Clin Gastroenterol; 2014 Aug; 48(7):644-9. PubMed ID: 24201999
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.
    Lin SM; Yu ML; Lee CM; Chien RN; Sheen IS; Chu CM; Liaw YF
    J Hepatol; 2007 Jan; 46(1):45-52. PubMed ID: 17107734
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of hepatitis B core-related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta-analysis.
    Cao QH; Liu H; Yan LJ; Wang HC; Ding ZN; Mao XC; Li RZ; Pan GQ; Zhang X; Tian BW; Han CL; Dong ZR; Tan SY; Wang DX; Yan YC; Li T
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1464-1475. PubMed ID: 38686439
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study.
    Ahn J; Lim JK; Lee HM; Lok AS; Nguyen M; Pan CQ; Mannalithara A; Te H; Reddy KR; Trinh H; Chu D; Tran T; Lau D; Leduc TS; Min A; Trong Le L; Bae H; Van Tran S; Do S; Hann HW; Wong C; Han S; Pillai A; Park JS; Tong M; Scaglione S; Woog J; Kim WR
    Am J Gastroenterol; 2016 Sep; 111(9):1297-304. PubMed ID: 27325221
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reasons to consider early treatment in chronic hepatitis B patients.
    Koffas A; Petersen J; Kennedy PT
    Antiviral Res; 2020 May; 177():104783. PubMed ID: 32217150
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.
    Fattovich G; Bortolotti F; Donato F
    J Hepatol; 2008 Feb; 48(2):335-52. PubMed ID: 18096267
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis.
    Lee HA; Kim SU; Seo YS; Ahn SH; Rim CH
    Hepatol Commun; 2023 Feb; 7(2):e0011. PubMed ID: 36691962
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients.
    Chen TM; Chang CC; Huang PT; Wen CF; Lin CC
    Aliment Pharmacol Ther; 2013 Jan; 37(2):243-51. PubMed ID: 23171385
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
    Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
    Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma.
    Tsai JF; Jeng JE; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
    Br J Cancer; 1996 Jun; 73(12):1498-502. PubMed ID: 8664119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Improved survival and less hepatocellar carcinoma following the successful treatment of chornic hepatitis B].
    Jansen PL
    Ned Tijdschr Geneeskd; 2005 Jul; 149(27):1495-7. PubMed ID: 16032993
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Miyake Y; Kobashi H; Yamamoto K
    J Gastroenterol; 2009; 44(5):470-5. PubMed ID: 19308310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.
    Song BC; Suh DJ; Lee HC; Chung YH; Lee YS
    Hepatology; 2000 Oct; 32(4 Pt 1):803-6. PubMed ID: 11003626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chronic hepatitis B virus infection in Asian countries.
    Merican I; Guan R; Amarapuka D; Alexander MJ; Chutaputti A; Chien RN; Hasnian SS; Leung N; Lesmana L; Phiet PH; Sjalfoellah Noer HM; Sollano J; Sun HS; Xu DZ
    J Gastroenterol Hepatol; 2000 Dec; 15(12):1356-61. PubMed ID: 11197043
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
    Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection.
    Murata K; Sugimoto K; Shiraki K; Nakano T
    World J Gastroenterol; 2005 Nov; 11(43):6848-52. PubMed ID: 16425395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.